• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma.

作者信息

Hyun Jae-Won, Kim Geun Soo, Kim Su-Hyun, Cho Joong-Yang, Kim Ho Jin, Lee Geon Kook, Kim Hak Jin, Kwon Sung Uk

机构信息

Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea.

Department of Neurology, Ilsan Paik Hospital, Inje University, College of Medicine, Goyang, Korea.

出版信息

Clin Lung Cancer. 2020 Mar;21(2):e74-e77. doi: 10.1016/j.cllc.2019.10.008. Epub 2019 Oct 19.

DOI:10.1016/j.cllc.2019.10.008
PMID:31718909
Abstract
摘要

相似文献

1
Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma.帕博利珠单抗治疗难治性胸腺瘤后发生的致命性同时多器官衰竭
Clin Lung Cancer. 2020 Mar;21(2):e74-e77. doi: 10.1016/j.cllc.2019.10.008. Epub 2019 Oct 19.
2
Response to Pembrolizumab in a Patient with Relapsing Thymoma.复发胸腺瘤患者对帕博利珠单抗的反应
J Thorac Oncol. 2016 Dec;11(12):e147-e149. doi: 10.1016/j.jtho.2016.07.018. Epub 2016 Aug 4.
3
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.帕博利珠单抗治疗难治或复发胸腺癌患者的开放性 II 期临床试验。
J Clin Oncol. 2019 Aug 20;37(24):2162-2170. doi: 10.1200/JCO.2017.77.3184. Epub 2018 Jun 15.
4
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.派姆单抗治疗胸腺癌患者的单臂、单中心、2 期研究。
Lancet Oncol. 2018 Mar;19(3):347-355. doi: 10.1016/S1470-2045(18)30062-7. Epub 2018 Jan 26.
5
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.晚期胸腺癌中抗程序性死亡配体 1（PD-L1）抗体（avelumab）治疗的疗效和耐受性。
J Immunother Cancer. 2019 Oct 21;7(1):269. doi: 10.1186/s40425-019-0723-9.
6
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.免疫检查点抑制剂诱发的重症肌无力，见于一名患有晚期非小细胞肺癌且有胸腺瘤既往史的患者。
Clin Lung Cancer. 2019 Jul;20(4):e489-e491. doi: 10.1016/j.cllc.2019.04.007. Epub 2019 Apr 19.
7
Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.纳武利尤单抗治疗 B3 型胸腺瘤时导致的致命性心肌炎和横纹肌溶解症。
Clin Toxicol (Phila). 2018 Jul;56(7):667-671. doi: 10.1080/15563650.2017.1401079. Epub 2017 Nov 10.
8
Corneal melting in a case undergoing treatment with pembrolizumab.帕博利珠单抗治疗病例中的角膜溶解
Clin Exp Optom. 2020 May;103(3):379-381. doi: 10.1111/cxo.12973. Epub 2019 Nov 6.
9
Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.免疫治疗相关毒性事件和单剂量帕博利珠单抗治疗转移性胸腺瘤后的显著缓解：一例报告。
Front Immunol. 2021 Apr 15;12:621858. doi: 10.3389/fimmu.2021.621858. eCollection 2021.
10
Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma.帕博利珠单抗治疗转移性非小细胞肺癌合并胸腺瘤切除术后患者并发重症肌无力和心肌炎
Clin Lung Cancer. 2022 Jun;23(4):e293-e295. doi: 10.1016/j.cllc.2021.12.001. Epub 2021 Dec 10.

引用本文的文献

1
Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis.免疫检查点抑制剂相关心肌炎的临床前小鼠模型
Nat Cardiovasc Res. 2025 May;4(5):526-538. doi: 10.1038/s44161-025-00640-2. Epub 2025 May 7.
2
Immune checkpoint inhibitor myocarditis in thymic epithelial tumors: a case report and literature review.胸腺上皮肿瘤中的免疫检查点抑制剂相关性心肌炎：一例报告及文献综述
Transl Cancer Res. 2024 Feb 29;13(2):1208-1218. doi: 10.21037/tcr-23-2212. Epub 2024 Feb 28.
3
Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
胸腺改变与免疫检查点抑制剂性心肌炎易感性。
Nat Med. 2023 Dec;29(12):3100-3110. doi: 10.1038/s41591-023-02591-2. Epub 2023 Oct 26.
4
Pacemakers and methylprednisolone pulse therapy in immune-related myocarditis concomitant with complete heart block.起搏器与甲基强的松龙脉冲疗法治疗免疫相关性心肌炎合并完全性心脏传导阻滞
Open Med (Wars). 2022 Dec 20;17(1):2109-2116. doi: 10.1515/med-2022-0611. eCollection 2022.
5
Multisystem immune-related adverse events due to toripalimab: Two cases-based review.托法替布引起的多系统免疫相关不良事件：基于两例病例的回顾
Front Cardiovasc Med. 2022 Nov 25;9:1036603. doi: 10.3389/fcvm.2022.1036603. eCollection 2022.
6
Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.韩国国家癌症中心的免疫检查点抑制剂严重神经肌肉免疫相关不良事件。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5583-5589. doi: 10.1007/s00432-022-04516-x. Epub 2022 Dec 10.
7
Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data.免疫检查点抑制剂诱导的心肌炎的内在差异：真实世界数据的回顾性分析
Front Pharmacol. 2022 Jul 5;13:914928. doi: 10.3389/fphar.2022.914928. eCollection 2022.
8
A systematic review of myasthenia gravis complicated with myocarditis.重症肌无力合并心肌炎的系统评价。
Brain Behav. 2021 Aug;11(8):e2242. doi: 10.1002/brb3.2242. Epub 2021 Jun 9.
9
Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.免疫治疗相关毒性事件和单剂量帕博利珠单抗治疗转移性胸腺瘤后的显著缓解：一例报告。
Front Immunol. 2021 Apr 15;12:621858. doi: 10.3389/fimmu.2021.621858. eCollection 2021.
10
Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung.病例报告：肺大细胞神经内分泌癌患者接受帕博利珠单抗治疗后发生致命性多器官衰竭和异时性肺炎
Front Pharmacol. 2021 Jan 29;11:569466. doi: 10.3389/fphar.2020.569466. eCollection 2020.